Clinical trials: Staphylococcus (S.) Aureus Infection
Bacteremia, Staphylococcus Aureus
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to…
- Conditions
- Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph
- Trial name
- diSArm (NCT05184764)
- Testing
- AP-SA02
- Where
- 28 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
Staphylococcus aureus (S.aureus) is a bacterium that causes many painful skin and soft tissue conditions, such as scalded-skin syndrome, boils, or impetigo.
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
- Trial name
- MRSA (NCT00822276)
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Network Adaptive Platform Trial
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with…
- Trial name
- SNAP (NCT05137119)
- Testing
- Cefazolin, Penicillin, Clindamycin
- Where
- 161 sites in United States, Australia and 11 more
- Volunteers
- 8,000 people
- Sponsor
- University of Melbourne
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect
Infective Endocarditis, Infection Staphylococcal
NExt-Generation Sequencing and Cell Culture-based Characterization of S. Aureus in Infective Endocarditis
Infective endocarditis is a deadly disease with a mortality rate between 20 and 40%. Antibiotic therapy is of utmost importance. It is primarily guided by microbial results from positive blood culture.
- Trial name
- NESSIE (NCT04257292)
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Jena University Hospital
Staphylococcus (S.) Aureus Infection
Staphylococcus Aureus Caught in Action at the Site of Infection
This study is to obtain a comprehensive view of S. aureus adaptations in the infected human host and (i) to improve the understanding of the interface between antibiotic therapy, resistance development and virulence factor…
- Trial name
- PROSA (NCT04781569)
- Testing
- data collection, blood draw, nose swabs
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Staphylococcus Aureus
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens: Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in…
- Trial name
- NCT03140423
- Testing
- Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization
- Where
- 137 sites in United States
- Volunteers
- 353,323 people
- Sponsor
- Harvard Pilgrim Health Care
Staphylococcal Infection
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
The objective of this trial is 1) to evaluate the safety and clinical acceptability of a 5-day course of mupirocin applied every 8 hours (± 2 hours) to the nares, umbilical and perianal areas of infants residing in the ICU.
- Trial name
- NCT01827358
- Testing
- Mupirocin calcium
- Where
- 6 sites in United States
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
Pneumonia Due to Staphylococcus Aureus
Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)
The objectives of this study are to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical outcome of patients who have severe pneumonia caused by Staphylococcus aureus (S.
- Trial name
- NCT01589185
- Testing
- KBSA301
- Where
- 18 sites in United States, Belgium and 2 more
- Volunteers
- 48 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Diabetic Foot, Foot Ulcer
Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds
The primary objective of this study is to detect differences in anti-S. aureus antibody assays (IgM, IgA, IgG and its subclasses) between (1) a group of patients with bacteremia due to a chronic wound (cases) and (2) a group of…
- Conditions
- Diabetic Foot, Foot Ulcer, Leg Ulcer, Bacteremia
- Trial name
- ORISA (NCT01551667)
- Testing
- Antibody assays for S. aureus, Basic blood work
- Where
- 6 sites in France
- Volunteers
- 69 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Staphylococcus Aureus, Health Care Associated Infection
Reducing Perioperative S. Aureus Transmission
The purpose of this study is to prevent the spread of S. aureus, a dangerous bacterium, within the operating room and between patients undergoing surgery.
- Conditions
- Staphylococcus Aureus, Health Care Associated Infection, Health Care Worker Patient Transmission
- Trial name
- NCT03638947
- Testing
- Swab and decolonization using povidone-iodine cleansing
- Where
- United States
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- Randy Loftus
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Staphylococcus Aureus, Bacteremia
Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score < 3
Staphylococcus aureus is the most frequent cause of both healthcare-associated and community-acquired bloodstream infections worldwide.
- Conditions
- Staphylococcus Aureus, Bacteremia, Infective Endocarditis
- Trial name
- VIRSTA-VAL (NCT06457386)
- Testing
- systematic echocardiography, no echocardiography arm
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bacteria Infection Mechanism
Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia
Staphylococcus aureus bacteremia is a serious infection associated with a high mortality rate (with or without associated infective endocarditis (IE)), long hospital stays and multiple complications, due to the terrain in which…
- Trial name
- RISTA (NCT06594250)
- Testing
- Nasal swab, Venous sampling, Antibiotic treatment
- Where
- France
- Volunteers
- 405 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pneumonia, Ventilator-associated, Pneumonia, Staphylococcal
Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.
The purpose of this study is the prevention of Staphylococcus aureus pneumonia in mechanically ventilated subjects heavily colonized with S. aureus.
- Trial name
- NCT02940626
- Testing
- ASN100
- Where
- 93 sites in United States, Austria and 14 more
- Volunteers
- 155 people
- Sponsor
- Arsanis, Inc.
Nurse's Role, Surgical Site Infection
Effectiveness of the Decolonization Circuit of S. Aureus, Reducing Infection in Primary Arthroplasty of the Lower Limb
Lower limb joint replacement surgery is one of the most prevalent globally. In our center, more than 400 lower limb arthroplasties (LLA) are performed annually.
- Conditions
- Nurse's Role, Surgical Site Infection, Patient Satisfaction
- Trial name
- NCT05158322
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Corporacion Parc Tauli
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
This is a multicenter, randomized, evaluator-blinded, comparator-controlled study. Participants were to be randomized (1:1) to daptomycin or comparator, stratified by degree of renal impairment (creatinine clearance [CLcr] 30 …
- Conditions
- Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
- Trial name
- RENSE (NCT01104662)
- Testing
- Vancomycin, Daptomycin, Semi-Synthetic Penicillin
- Where
- 10 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus
Decolonization of Patients Carrying S. Aureus Before Cardiac Surgery: Study of the Risk Factors Associated With Failure
Staphylococcus aureus nasal carriage is a well-known risk factor for S. aureus surgical site infections (SSI). According to a recent study demonstrating 60% reduction risk of SSI due this bacterium after patients' screening and…
- Trial name
- STAdécol (NCT03685487)
- Testing
- decolonization, compliance questionnaire
- Where
- France
- Volunteers
- 215 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne